Gliosarcoma as a rare variant of glioblastoma: 6-Case clinical trial and literature review
Department of Neurosurgery, Mohammed V Military Teaching Hospital, Rabat, Morocco.
Case Study
World Journal of Advanced Research and Reviews, 2024, 23(02), 991–996
Article DOI: 10.30574/wjarr.2024.23.2.2396
Publication history:
Received on 23 June 2024; revised on 07 August 2024; accepted on 09 August 2024
Abstract:
Gliosarcoma is a rare and highly malignant central nervous system tumor that accounts for 1% to 8% of glioblastomas; it usually occurs in middle-aged and older adults between 40 and 60 years of age and is rare in children. Here in, we present a retrospective study of 6 cases of gliosarcomas diagnosed at the Mohamed V Military Instruction Hospital (HMIMV). A review of clinical, radiological, therapeutic and evolutionary data was carried out. Treatment consisted of a complete macroscopic resection for 5 patients, completed with an adjuvant radiotherapy with temozolomide, the median survival time of our cases was 9,4 months. As a conclusion, there is a lack of a definitive treatment that significantly improves prognosis for gliosacroma’s tumor, so more case reports of GS should be conducted, which would allow a clearer diagnosis and improved treatment methods and prognoses.
Keywords:
Glioblastoma; Gliosarcoma; Isocitrate Dehydrogenase; Brain Tumor; Macroscopic resection; Temozolomide.
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0